FIELD: medicine, pharmacy. SUBSTANCE: invention relates to solid pharmaceutical compositions. Form has a homogeneous base and therapeutically active substance at the following ratio, wt.-%: crystalline calcium antagonist of dihydripyridine type 5-60; hydroxypropylmethylcellulose 2-50, and pharmaceutically acceptable vehicles up to 100. EFFECT: simplified form. 9 cl, 3 dwg, 5 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
THREE-PHASE PHARMACEUTICAL FORM WITH CONSTANT AND CONTROLLED RELEASE OF AMORPHOUS ACTIVE INGREDIENT FOR SINGLE DAILY ADMINISTRATION | 1996 |
|
RU2161956C2 |
ORAL PHARMACEUTICAL COMPOSITION SUITABLE FOR IMPROVING EFFECTIVENESS OF TREATMENT OF MOTOR DISORDERS | 2013 |
|
RU2670272C2 |
COFORMULATED DRUG FOR CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THERAPY | 2007 |
|
RU2464014C2 |
SOLID MEDICINAL FORM COMPRISING RAMIPRIL AS INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME AND DIHYDROPYRIDINE COMPOUND | 1995 |
|
RU2184563C2 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
COMBINED CONTROLLED-RELEASE PHARMACEUTICAL AGENT CONTAINING DIHYDROPYRIDINE CALCIUM CANAL BLOCKERS AND HMG-CoA-REDUCTASE INHIBITORS | 2007 |
|
RU2450804C2 |
USING FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC FAILURE, MYOCARDIAL INFARCTION AND ANGINA | 2007 |
|
RU2459621C2 |
STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL | 1998 |
|
RU2188636C2 |
PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
COATED COMPOUND CONTAINING PHARMACEUTICAL AGENT | 2004 |
|
RU2372893C2 |
Authors
Dates
1998-11-27—Published
1993-02-16—Filed